Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $63.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 325.10% from the stock’s previous close.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Trading Down 5.8 %

NASDAQ ARCT opened at $14.82 on Tuesday. The company has a 50-day moving average price of $18.62 and a two-hundred day moving average price of $21.89. The stock has a market cap of $401.43 million, a price-to-earnings ratio of -6.68 and a beta of 2.62. Arcturus Therapeutics has a 52 week low of $14.35 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the previous year, the firm posted ($0.61) EPS. As a group, equities research analysts expect that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 15.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Arcturus Therapeutics during the 3rd quarter worth about $42,000. Quest Partners LLC raised its holdings in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Arcturus Therapeutics in the second quarter valued at $142,000. Finally, Point72 DIFC Ltd bought a new position in shares of Arcturus Therapeutics during the second quarter valued at $188,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.